Received Nov 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | P2443 | — |
A 63 years old female patient received a dose of Havrix an 5 months later a dose of Twinrix.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 63-year-old female patient who received HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Previously administered products included Havrix (1st dose received on 14th April 2025). On 29-SEP-2025, the patient received Twinrix. On 29-SEP-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: A 63 years old female patient received a dose of Havrix an 5 months later a dose of Twinrix.). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 22-OCT-2025 The patient received Havrix on 4/14/2025 and then the next HepA dose was a dose of Twinrix on 9/29/2025. The reporter asked what was the dosing schedule to follow.